AccessDX

Focused pharmacogenomic testing panel for targeted medication response assessment.

UTI PROx panel combines RT-PCR and culture to rapidly detect uropathogens and coinfections while improving treatment speed, efficacy, and antibiotic stewardship.

Pharmacogenomics (PGx) testing helps doctors determine the safest and most effective medications and dosages based on an individual’s genetic information.

A focused, single-gene test for DPD enzyme deficiency that provides actionable, high-evidence drug-gene interaction insights for oncology patients.

Custom-designed panel that includes 33 genes known to harbor variants linked to the hereditary cancer syndrome.

Single gene pharmacogenetic test targeting Dihydropyrimidine Dehydrogenase (DPYD) for oncology and clinical pharmacogenomics.

A precision medicine program for long-term and post-acute care facilities designed to reduce readmissions, emergency department visits, falls, and polypharmacy through adverse drug interaction risk assessments and pharmacogenetic profiling.

Identifies fungal and bacterial microbial wound infections with molecular analysis for superior precision and speed in species and antibiotic resistance gene identification over traditional cultures.

Identifies fungal and bacterial microbial toenail infections and antibiotic resistance genes with RT-PCR testing for superior precision and speed over traditional cultures.

Software tool to assist clinicians in interpreting genetic test results and making precision prescribing decisions.

Detects enteropathogenic viruses, bacteria, and parasites causing gastroenteritis and antibiotic drug resistance through multiplex quantitative RT-PCR.

Rapidly detects and differentiates a wide range of viral and bacterial pathogens.

An FDA-compliant COVID-19 reverse-transcription polymerase chain reaction (RT-PCR) test for quick SARS-CoV-2 identification, enabling faster treatment.

Uses RT-PCR testing to detect both A & B influenza virus strains quickly.